Skip to main navigation Skip to search Skip to main content

The US national registry for childhood interstitial and diffuse lung disease: Report of study design and initial enrollment cohort

  • for the chILD Registry Collaborative
  • University of Missouri
  • University of Washington
  • Case Western Reserve University
  • University of Colorado Anschutz Medical Campus
  • Harvard University
  • Washington University St. Louis
  • Vanderbilt University
  • University of Pittsburgh
  • University of North Carolina at Chapel Hill
  • Stanford University
  • Children's Mercy Hospitals and Clinics
  • Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • University of Minnesota Twin Cities
  • Johns Hopkins University
  • Indiana University Bloomington
  • Northwestern University
  • University of Southern California
  • University of Michigan, Ann Arbor
  • Columbia University
  • University of California at San Francisco
  • Oregon Health and Science University
  • University of Pennsylvania

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Introduction: Childhood interstitial and diffuse lung disease (chILD) encompasses a broad spectrum of rare disorders. The Children's Interstitial and Diffuse Lung Disease Research Network (chILDRN) established a prospective registry to advance knowledge regarding etiology, phenotype, natural history, and management of these disorders. Methods: This longitudinal, observational, multicenter registry utilizes single-IRB reliance agreements, with participation from 25 chILDRN centers across the U.S. Clinical data are collected and managed using the Research Electronic Data Capture (REDCap) electronic data platform. Results: We report the study design and selected elements of the initial Registry enrollment cohort, which includes 683 subjects with a broad range of chILD diagnoses. The most common diagnosis reported was neuroendocrine cell hyperplasia of infancy, with 155 (23%) subjects. Components of underlying disease biology were identified by enrolling sites, with cohorts of interstitial fibrosis, immune dysregulation, and airway disease being most commonly reported. Prominent morbidities affecting enrolled children included home supplemental oxygen use (63%) and failure to thrive (46%). Conclusion: This Registry is the largest longitudinal chILD cohort in the United States to date, providing a powerful framework for collaborating centers committed to improving the understanding and treatment of these rare disorders.

Original languageEnglish
Pages (from-to)2236-2246
Number of pages11
JournalPediatric Pulmonology
Volume59
Issue number9
Early online dateJul 4 2023
DOIs
StatePublished - Sep 2024

Funding

The authors thank all the research coordinators and study staff at the participating institutions for assisting with subject recruitment, consent, and oversight of regulatory processes. We thank Errine Garnett (Vanderbilt) for management of the initial Registry development. We also thank Alicia Hurnton (CHOP) for project management and coordination of the Registry and Emma Escobar at CHOP for database development and support. Supported in part by the NIH/NHLBI K24 HL143281 (LRY).

Funder number
K24 HL143281

    Keywords

    • NEHI
    • interstitial lung disease
    • rare lung disease

    Fingerprint

    Dive into the research topics of 'The US national registry for childhood interstitial and diffuse lung disease: Report of study design and initial enrollment cohort'. Together they form a unique fingerprint.

    Cite this